Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

c-Fms

Colony stimulating factor 1 receptor (CSF1R), also known as macrophage colony-stimulating factor receptor (M-CSFR), and CD115 (Cluster of Differentiation 115), is a cell-surface protein encoded, in humans, by the CSF1R gene (known also as c-FMS). It is a receptor for a cytokine called colony stimulating factor 1.

  • Edicotinib
    T151991142363-52-7
    Edicotinib (JNJ-527) is a brain penetrant and orally active inhibitor of the colony-stimulating factor-1 receptor (IC50: 3.2 nM). It shows less inhibitory effects on KIT and FLT3 (IC50: 20 nM and 190 nM). It has the potential for Alzheimer's disease and rheumatoid arthritis treatment.
    • $64
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
  • Pexidartinib
    T21151029044-16-3
    Pexidartinib (PLX-3397) is a capsule formulation containing a small-molecule receptor tyrosine kinase (RTK) inhibitor of KIT, CSF1R and FLT3 with potential antineoplastic activity.
    • $40
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • PLX5622
    T71001303420-67-8
    PLX5622 is a highly selective brain penetrant and oral active CSF1R inhibitor.
    • $97
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Hot
    TargetMol | Citations Cited
  • c-Fms-IN-1
    T10643885703-64-0In house
    c-Fms-IN-1 is an inhibitor of c-FMS kinase (IC50 = 0.8 nM).
    • $42
    In Stock
    Size
    QTY
  • c-Fms-IN-13
    T61589885704-58-5In house
    c-Fms-IN-13 (compound 14) is a potent FMS kinase inhibitor (IC50= 17 nM). c-Fms-IN-13 is an anti-inflammatory agent.
    • $39
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • c-Fms-IN-2
    T10775791587-67-2In house
    c-Fms-IN-2 is an inhibitor of c-FMS kinase (IC50 = 24 nM).
    • $88
    In Stock
    Size
    QTY
  • c-Fms-IN-3
    T10649885704-21-2In house
    c-Fms-IN-3 is a novel inhibitor of the c-FMS and can be used in studies about antirheumatic and anti-inflammatory diseases.
    • $46
    In Stock
    Size
    QTY
  • OSI-930
    T2624728033-96-3
    OSI-930, an orally active inhibitor of c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2), targets cancer cell proliferation and blood vessel growth (angiogenesis) in tumors.
    • $47
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Sotuletinib
    T6119953769-46-5
    Sotuletinib (BLZ945) is an orally active, effective and specific CSF-1R inhibitor (IC50: 1 nM), >1000-fold selective against its closest receptor tyrosine kinase homologs.
    • $31
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Anti-Mouse GM-CSF Antibody (MP1-22E9)
    T80585
    Anti-Mouse GM-CSF Antibody is a rat-derived IgG2a isotype inhibitor that targets mouse granulocyte-macrophage colony-stimulating factor (GM-CSF).
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • AZ304
    T5172942507-42-8
    AZ304 is an ATP-competitive dual BRAF kinase inhibitor, potently inhibits BRAF (WT), BRAF (V600E), and wild type CRAF (IC50s: 79/38/68 nM).
    • $42
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Gimsilumab
    T770251648796-29-5
    Gimsilumab (MORAb-022) is a humanized monoclonal antibody targeting granulocyte macrophage colony-stimulating factor for the study of COVID-19-induced inflammation and hypoxemia.
    • $169
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Emactuzumab
    T767761448221-67-7
    Emactuzumab(RG 7155) is a monoclonal antibody against colony-stimulating factor-1 receptor targeting tumor-associated macrophages (TAMs) Emactuzumab has antitumor activity and inhibits activation of colony-stimulating factor 1 receptor (CSF1R) Emactuzumab has a high affinity for CSF-1R with a Ki value of 0.2 nM. Emactuzumab blocks CSF-1R dimerization and can be used to study cancers such as diffuse tenosynovial giant cell tumor (dt-GCT).
    • $328
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • JNJ-6204
    T695222765264-50-2
    JNJ-6204 is a deuterated compound that efficiently inhibits CSNK1D and CSNK1E.
    • $195
    Backorder
    Size
    QTY
  • c-Fms-IN-9
    T106481628574-50-4
    c-Fms-IN-9 is a c-FMS inhibitor. It inhibits unphosphorylated c-FMS kinase (uFMS) and uKIT (IC50s: <0.01 μM and 0.1-1 μM).
    • $1,670
    Backorder
    Size
    QTY
  • cFMS Receptor Inhibitor II
    T5586959860-85-6
    cFMS Receptor Inhibitor II is a CSF1R kinase inhibitor
    • $42
    In Stock
    Size
    QTY
  • CSF1R-IN-2
    T131942271119-26-5
    CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).
    • $64
    In Stock
    Size
    QTY
  • Linifanib
    T2514796967-16-3
    Linifanib (AL-39324) (ABT-869) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR (IC50: 4 nM), CSF-1R (IC50: 3 nM), Flt-1/3 (IC50: 3/4 nM) and PDGFRβ (IC50: 66 nM). Linifanib may exhibit potent antiproliferative and apoptotic effects on tumor cells whose proliferation is dependent on mutant kinases, such as FMS-related tyrosine kinase receptor-3 (FLT3).
    • $43
    In Stock
    Size
    QTY
  • Ki20227
    T4315623142-96-1
    Ki-20227 is a specific c-Fms tyrosine kinase(CSF1R) inhibitor (IC50: 2 nM). It also has certain inhibitory against VEGFR2(IC50: 12 nM) and c-Kit/PDGFRβ(IC50: 451/217 nM), respectively.
    • $39
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Vimseltinib
    T106521628606-05-2
    Vimseltinib (DCC-3014) is a c-FMS (CSF-IR) and c-Kit dual inhibitor (IC50s: <0.01 μM and 0.1-1 μM).
    • $84
    In Stock
    Size
    QTY
  • IACS-9439
    T697592231259-57-5
    IACS-9439 is a potent, selective, and orally active inhibitor of CSF1R, exhibiting a K(i) of 1 nM. It is applicable in the research of advanced solid tumors [1].
    • $1,520
    Backorder
    Size
    QTY
  • AEE788
    T2116497839-62-0
    AEE788 (NVP-AEE 788) has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Brain and Central Nervous System Tumors.
    • $39
    In Stock
    Size
    QTY
  • Masitinib
    T2609790299-79-5
    Masitinib (AB1010) is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 2008 it has been distributed under the commercial name Masivet. It has been available in Europe since the second part of 2009. In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.
    • $31
    In Stock
    Size
    QTY
  • CSF1R-IN-1
    T108942095849-04-8
    CSF1R-IN-1 is a CSF1R inhibitor with IC50 of 0.5 nM.
    • $105
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • CSF1R-IN-3
    T640662760584-90-3
    CSF1R-IN-3 is an orally effective CSF-1R inhibitor with an IC50 value of 2.1 nM. CSF1R-IN-3 has anti-proliferative activity against colorectal cancer cells. CSF1R-IN-3 exhibits anti-tumour effects and immune enhancing effects by inhibiting the migration of macrophages and inducing the reprogramming of M2-type macrophages to M1-type macrophages, thus exhibited activity against colorectal cancer cells.
    • $139
    In Stock
    Size
    QTY
  • CSF1R-IN-17
    T79472
    CSF1R-IN-17 (compound 9) is a potent, selective antagonist of CSF1R, exhibiting an inhibition concentration half-maximum (IC50) of 0.2 nM. It is capable of inhibiting osteoclast differentiation [1].
    • Inquiry Price
    Size
    QTY
  • Cerdulatinib hydrochloride
    T61041369761-01-2
    Cerdulatinib hydrochloride (PRT2070 hydrochloride) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. Also inhibits 19 other tested kinases with IC50 less than 200 nM.
    • $37
    In Stock
    Size
    QTY
  • Nampt-IN-1
    T43761698878-14-6
    Nampt-IN-1 (LSN3154567) (LSN3154567) is a potent and selective NAMPT inhibitor. Nampt-IN-1 inhibits purified NAMPT with an IC50 of 3.1 nM.
    • $33
    In Stock
    Size
    QTY
  • Chiauranib
    T355701256349-48-0
    Chiauranib is a multi-target inhibitor against tumor angiogenesis and exhibits potent anticancer effects. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF1R, with IC50 values ranging from 1-9 nM.
    • $83
    In Stock
    Size
    QTY
  • c-Fms-IN-14
    T798151898210-99-5
    c-Fms-IN-14 (Example 76) is a potent inhibitor of the c-Fms kinase with an IC50 of 4 nM, utilized in cancer and autoimmune disease research [1].
    • Inquiry Price
    Size
    QTY
  • PLX647
    T1925873786-09-5
    PLX647 is a highly selective dual FMS/KIT kinase inhibitor (IC50: 28/16 nM).
    • $38
    5 days
    Size
    QTY
  • c-Fms-IN-6
    T106451628574-81-1
    c-Fms-IN-6 is a potent inhibitor of c-FMS (IC50 ≤10 nM for unphosphorylated c-FMS) and also weakly inhibits unphosphorylated c-KIT and PDGFR (IC50: > 1 μM).
    • $1,670
    Backorder
    Size
    QTY
  • Pazopanib Hydrochloride
    T6930635702-64-6
    Pazopanib Hydrochloride (Votrient HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
    • $48
    In Stock
    Size
    QTY
  • PRN1371
    TQ00151802929-43-6
    PRN1371 is a specific and potent FGFR1-4 and CSF1R inhibitor (IC50s: 0.6/1.3/4.1/19.3/8.1 nM for FGFR1/2/3/4 and CSF1R).
    • $74
    In Stock
    Size
    QTY
  • cFMS Receptor Inhibitor IV
    T60087959626-45-0
    cFMS Receptor Inhibitor IV is an inhibitor of c-Fms tyrosine kinase.
    • $84
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Onatasertib
    T33511228013-30-6
    Onatasertib (CC223) is an orally available mTOR inhibitor with potential antitumor activity. Onatasertib inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. Onatasertib is a potent mTOR kinase inhibitor (IC50: 16 nM), with >150-fold sensitivity than the related lipid kinase PI3Kα (IC50: 4 μM).
    • $35
    In Stock
    Size
    QTY
  • Sotuletinib dihydrochloride
    T786032222138-40-9
    Sotuletinib (BLZ945) dihydrochloride is an orally administered, blood-brain barrier-permeable inhibitor specifically targeting CSF1-R with an IC50 of 1 nM. It promotes apoptosis in tumor cells and significantly restricts tumor growth in murine models, proving useful in cancer and amyotrophic lateral sclerosis (ALS) studies [1].
    • $1,520
    Backorder
    Size
    QTY
  • Pimicotinib
    T791572253123-16-7
    Pimicotinib (ABSK021) is a potent CSF1R inhibitor with antitumor activity and can be used to study advanced solid tumors.
    • $59
    In Stock
    Size
    QTY
  • GW2580
    T2659870483-87-7
    GW2580 (SC-203877) is a specific, oral-bioavailable CSF-1R inhibitor for c-FMS.
    • $43
    In Stock
    Size
    QTY
  • PF 477736
    T6028952021-60-2
    PF 477736 (PF-736,PF-00477736) is a specifc, effective and ATP-competitive Chk1 inhibitor (Ki: 0.49 nM ) and also inhibits FGFR3, Aurora-A, VEGFR2, Flt3, Fms (CSF1R), Ret and Yes.
    • $45
    In Stock
    Size
    QTY
  • PLX5622 hemifumarate
    T12505
    PLX5622 hemifumarate is a highly selective brain penetrant and orally active CSF1R inhibitor with an IC 50 of 0.016 μM and Ki of 5.9 nM. PLX5622 hemifumarate allows for extended and specific microglial elimination, preceding and during pathology development. In vivo, PLX5622 hemifumarate demonstrates desirable PK properties in varies animals [1] [2].
    • $1,168
    Backorder
    Size
    QTY
  • Anumigilimab
    T769082416593-08-1
    Anumigilimab (CSL-324) is a fully human therapeutic anti-G-CSFR antibody with potential anti-tumor activity for the study of inflammation.
    • $247
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale